Ovarian Reserve in Premenopausal Breast Cancer

Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer

NCT01298362 ·Status: COMPLETED

Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve

NCT02113553 ·Status: TERMINATED ·Phase: PHASE2

Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer

NCT00293540 ·Status: COMPLETED ·Phase: PHASE3

A Real-world Study on the Compliance of OFS-assisted Endocrine Therapy for Hormone Receptor-positive(HR+) Premenopausal Breast Cancer

NCT07180914 ·Status: NOT_YET_RECRUITING

Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane

NCT00291798 ·Status: COMPLETED ·Phase: PHASE2

Assessing Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy

NCT07127315 ·Status: COMPLETED

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT00066690 ·Status: COMPLETED ·Phase: PHASE3

Premenopausal Endocrine Responsive Chemotherapy Trial

NCT00066807 ·Status: TERMINATED ·Phase: PHASE3

Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.

NCT02936206 ·Status: TERMINATED ·Phase: PHASE1

Follow-up of Sequential Chemotherapy and Stimulation for Fertility Preservation in Young Patients With Breast Cancer

NCT03795246 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Predictors of Ovarian Insufficiency in Young Breast Cancer Patients

NCT01197456 ·Status: COMPLETED

Evaluation of Individual Sensitivity to the Gonadotoxicity of Chemotherapy in Young Patients With Breast Cancer

NCT03731845 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer

NCT00090844 ·Status: TERMINATED ·Phase: PHASE2

Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer

NCT00146601 ·Status: COMPLETED ·Phase: PHASE2

Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer

NCT01814865 ·Status: WITHDRAWN ·Phase: PHASE2

Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers

NCT03495609 ·Status: COMPLETED ·Phase: PHASE4

Early Changes in Metabolic Health in Breast Cancer Patients Initiating Endocrine Therapy

NCT06623903 ·Status: NOT_YET_RECRUITING

Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer

NCT00352872 ·Status: TERMINATED

Investigating the Impact of Tamoxifen Therapy on Ovarian Aging

NCT01384526 ·Status: COMPLETED

Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure

NCT00555477 ·Status: TERMINATED ·Phase: PHASE2

Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer

NCT01622361 ·Status: UNKNOWN ·Phase: PHASE3

Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients

NCT02532400 ·Status: TERMINATED ·Phase: PHASE3

Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy

NCT00542594 ·Status: TERMINATED

Investigation of Sex Hormone Levels in Chinese Women With Invasive Breast Cancer

NCT02263846 ·Status: COMPLETED

The Benefits of Continued Use of Ovarian Function Suppression After 5 Years

NCT06050109 ·Status: RECRUITING